2015
DOI: 10.1016/s1470-2045(15)00169-2
|View full text |Cite
|
Sign up to set email alerts
|

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

20
448
5
17

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 538 publications
(490 citation statements)
references
References 34 publications
20
448
5
17
Order By: Relevance
“…Of all previously published numerical alterations in FL, only gain of chromosome 18 stood out as an independent prognostic marker. Our results confirm EZH2 as a strong prognostic marker in FL, with wild-type gene status associated with poor disease outcome (EF), 31,32 but other markers, such as EP300 and TNFRSF14, which have been implicated to have a significant, though minor, impact on prognosis, were not substantiated in our study. 31,54 This is likely due to selection bias and relative underrepresentation of poor prognosis patients in previous series for which our study design was specifically optimized.…”
Section: P-value and Fdrsupporting
confidence: 41%
See 3 more Smart Citations
“…Of all previously published numerical alterations in FL, only gain of chromosome 18 stood out as an independent prognostic marker. Our results confirm EZH2 as a strong prognostic marker in FL, with wild-type gene status associated with poor disease outcome (EF), 31,32 but other markers, such as EP300 and TNFRSF14, which have been implicated to have a significant, though minor, impact on prognosis, were not substantiated in our study. 31,54 This is likely due to selection bias and relative underrepresentation of poor prognosis patients in previous series for which our study design was specifically optimized.…”
Section: P-value and Fdrsupporting
confidence: 41%
“…Our results confirm EZH2 as a strong prognostic marker in FL, with wild-type gene status associated with poor disease outcome (EF), 31,32 but other markers, such as EP300 and TNFRSF14, which have been implicated to have a significant, though minor, impact on prognosis, were not substantiated in our study. 31,54 This is likely due to selection bias and relative underrepresentation of poor prognosis patients in previous series for which our study design was specifically optimized. This LLBC study design precludes integration of a complete multifactorial prognostic model such as the M7-FLIPI index, however, the prognostic trend of EZH2 as reported by Pastore et al follows the same direction as in our study, where statistical significance is reached and lack of significance of 4 other markers is confirmed.…”
Section: P-value and Fdrsupporting
confidence: 41%
See 2 more Smart Citations
“…With larger FL data sets, prognostic models such as the clinicogenetic risk model containing 7 genes (M7-FLIPI), which integrates the gene mutation status of multiple genes (including CARD11) with clinical risk factors, may provide additional guidance. 37 On the basis of the encouraging data regarding the prognostic significance of early interim FDG-PET/CT in Hodgkin lymphoma and DLBCL, we evaluated the prognostic significance of several PET parameters at baseline, day 8, and cycle 3 day 1. The decision to evaluate PET at day 8 was based on reports of the utility of very early PET with tyrosine kinase inhibitor therapy in other malignancies.…”
Section: Bartlett Et Almentioning
confidence: 99%